Resonance Health LtdASX: RHT

Liver Fibrosis Device - EPoC Study Results

· Issued by Resonance Health Ltd via ASX

Filed with ASX ·

ASX Announcement – 27 October 2026 LIVER FIBROSIS RESULTS OPEN UP GLP-1 BIOMARKER OPPORTUNITY Highlights • FibrosisAssessment aims to measure fibrosis in the liver using MRI sequences without expensive hardware or invasive contrast injections • Fibrosis in the liver is a key biomarker...

View Attachment

6ix is reading this filing.

Resonance Health Ltd on 6ix

Earlier from Resonance Health

Later from Resonance Health

All Resonance Health news releases